|
|
|
| Clinical effect of Biejia Ruangan Tablets combined with Entecavir in the treatment of chronic hepatitis B |
| SUN Xiu-guang1 XU Juan2 PAN Jin-ping1 |
1. Department of Hepatology, People′s Hospital of Yichun City, Jiangxi Province, Yichun 336000, China;
2. Rehab Branch, People′s Hospital of Yichun City, Jiangxi Province, Yichun 336000, China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Biejia Ruangan Tablets (BRT) combined with Entecavir (ETV)in the treatment of chronic hepatitis B (CHB). Methods A total of 174 CHB patients treated in People′s Hospital of Yichun City from September 2016 to December 2018 were selected as the research objects and divided into the control group and the observation group by random number table method, with 87 cases in each group. The control group was treated with ETV, and the observation group was treated with ETV and BRT. Liver inflammation grade, liver fibrosis grade, HBV DNA copy amount, serum alanine aminotransferase (ALT) and liver fibrosis index (hyaluronic acid [HA],type Ⅲprocollagen [PCⅢ], type Ⅳcollagen [Ⅳ-C], laminin [LN]) levels in the two groups were compared. Results At the 48th week of treatment, the grade of liver inflammation in the two groups were better than those before treatment,and the differences were statistically significant (P＜0.05). At the 48th week of treatment, there was no statistically significant difference in the grade of liver inflammation between the two groups (P＞0.05). At the 48th week of treatment,the grade of liver fibrosis in the observation group was better than that in the control group, and the difference was statistically significant (P＜0.05). Before treatment, there were no statistically significant differences in serum ALT, HA, PCⅢ, Ⅳ-C and LN levels between the two groups (P＞0.05). At the 48th week of treatment, the levels of ALT, HA, PCⅢ,Ⅳ-C and LN in the two groups were lower than those before treatment, and the differences were statistically significant(P＜0.05). At the 48th week of treatment, the levels of ALT, HA, PCⅢ, Ⅳ-C and LN in the observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in HBV DNA copy between the two groups before treatment, at the 12th, 24th and 48th week of treatment (P＞0.05). Conclusion BRT is an effective adjuvant therapy for CHB, and it is of great value in improving the process of liver fibrosis.
|
|
|
|
|
|
| [1] |
Tamaki N，Kurosaki M，Kirino S，et al.Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir[J].JGH Open，2019，4（3）：429-432.
|
| [2] |
Menne S，Wildum S，Steiner G，et al.Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon-α in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus[J].Hepatol Commun，2020，4（6）：916-931.
|
| [3] |
Huang C，Shen D，Sun S，et al.Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B：Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies[J].Medicine（Baltimore），2019，98（17）：e15297.
|
| [4] |
杨年欢，袁国盛，周宇辰，等.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化96 周的临床疗效[J].南方医科大学学报，2016，36（6）：775-779.
|
| [5] |
Chen CJ，Yu HC，Chang CW，et al.Efficacy of telbivudine and entecavir against virus reactivation in HBeAg-patients undergoing chemotherapy[J].Medicine（Baltimore），2020，99（22）：e20330.
|
| [6] |
蒋亚君，阮清发.FibroScan 评价恩替卡韦联合复方鳖甲软肝片治疗乙肝性肝硬化代偿期疗效的Meta 分析[J].中医临床研究，2020，12（9）：17-20.
|
| [7] |
任方元，段俊.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化疗效观察[J].现代中西医结合杂志，2019，28（31）：3496-3499.
|
| [9] |
于亚男，钟俊，刘晓雨，等.大黄蛰虫丸对实验性肝纤维化大鼠组织病理学及其细胞凋亡的影响[J].现代药物与临床，2020，35（2）：197-201.
|
| [13] |
徐云芳，赵志敏，张媛媛，等.扶正化瘀片联合恩替卡韦治疗对乙肝肝硬化患者的纤维化改善作用单中心观察[J].中国中西医结合消化杂志，2020，28（12）：909-914.
|
| [14] |
余钦，凌昌全.慢性乙型肝炎病毒感染的中医证候研究[J].中医肿瘤学杂志，2020，2（2）：89-93.
|
| [15] |
陈文佳，毛霞，郭晓东，等.从网络视角探讨复方鳖甲软肝片的抗肝癌潜能及其组方功效配伍特点[J].中国实验方剂学杂志，2020，26（24）：11-22.
|
| [8] |
施文娟，张妍，王兆勋，等.91 例丙氨酸氨基转移酶低于正常值上限二倍的慢性乙型肝炎患者肝组织病理特征与实验室指标的相关性[J/CD].中华实验和临床感染病杂志（电子版），2020，14（2）：138-143.
|
| [10] |
Wang HW，Lai HC，Hu TH，et al.On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma[J].Cancers（Basel），2020，12（5）：1177.
|
| [11] |
Kamal F，Khan MA.Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?[J].Gastroenterology，2020，158（8）：2311-2312.
|
| [12] |
Wani MA，Sodhi JS，Zargar SA，et al.Entecavir is Safe and Effective in Long Term for the Treatment of Hepatitis B in Immunocompromised Children[J].J Clin Exp Hepatol，2020，10（2）：150-154.
|
| [16] |
Zhou J，Chen XM，Liu SW，et al.Effects of Biejia Ruangan Tablet-containing serum on matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in cultured renal interstitial fibroblasts[J].Chin J Integr Med，2015，21（2）：152-156.
|
| [17] |
白金霞，戴领，陈红鸽，等.血清药理学与药代动力学整合模型的复方鳖甲软肝片日服用次数合理性研究[J].中国中药杂志，2013，38（14）：2394-2398.
|
| [18] |
Yang FR，Fang BW，Lou JS.Effects of Fufang Biejia Ruangan pills on hepatic fibrosis in vivo and in vitro[J].World J Gastroenterol，2013，19（32）：5326-5333.
|
| [19] |
成娟，邹磊，王大伟，等.复方鳖甲软肝片联合恩替卡韦治疗乙肝肝硬化的临床疗效及FibroScan 值改善效果评价[J].中国实用医药，2019，14（28）：77-78.
|
| [20] |
廖庆英，关蓉，蒋吟啸，等.复方鳖甲软肝片联合恩替卡韦治疗慢性乙型病毒性肝炎伴肝纤维化的系统评价[J].中国医院用药评价与分析，2019，19（9）：1031-1038.
|
|
|
|
